Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics Inc. has announced the amendment of exercise prices for over a million outstanding warrants to a uniform USD $5.00, following approval from the TSX Venture Exchange. In addition, a new warrant acceleration provision has been introduced, allowing the company to enforce exercise of the warrants if their common share price exceeds USD $6.50 for ten consecutive trading days. XORTX, a pharmaceutical company, focuses on the development of treatments for progressive kidney diseases and has several products in advanced stages of clinical development.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
